Monoclonal antibodies (mAbs) targeting specific cytokines, such as IL-5, IL-4/IL-13, and IgE, have provided significant benefits for patients with specific asthma phenotypes (Kardas et al., 2022). This evidence concerns the gene IL5 and asthma.